InMed Pharmaceuticals Extends Compliance Timeline with Nasdaq
Wednesday, 20 March 2024, 12:38
InMed Pharmaceuticals Compliance Extension Announcement
InMed Pharmaceuticals has received a 180-day compliance period extension from Nasdaq, allowing the company to address regulatory concerns.
Key Points:
- This extension safeguards InMed Pharmaceuticals' listing status on Nasdaq.
- The company's ordinary shares continue to trade without interruption during this period.
- The extension offers InMed Pharmaceuticals the opportunity to rectify compliance issues and ensure alignment with Nasdaq regulations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.